Plasmid DNA Manufacturing Market

Pages:
284
View Count:
25272
Delivery Formats:
PDF PPT Excel
Plasmid DNA Manufacturing Market

Lowest Price Guaranteed

download button Download Free Sample

sales@rootsanalysis.com

buynow button Buy Now

+44 (122) 391 1091

Plasmid DNA Manufacturing Market (2nd Edition) by Scale of Operation (Commercial, Clinical, and Preclinical), Grade of Plasmid DNA (GMP-Grade Plasmid DNA, High Quality Plasmid DNA, Research Grade Plasmid DNA), Application Area (Viral Vector Manufacturing, Gene Therapy Manufacturing, Cell Therapy Manufacturing, DNA Vaccine Manufacturing, and mRNA Vaccine Manufacturing), Therapeutic Area, End-user, and Geography- Trends and Global Forecast, 2026- 2035

Table of Contents

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary

Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity

Analysis

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Overview of Plasmid DNA

6.3. Structure of a plasmid DNA

6.4. Types of Plasmids (By

Function)

6.4.1. Fertility Plasmids

6.4.2. Resistance Plasmids

6.4.3. Virulence Plasmids

6.4.4. Degradative Plasmids

6.4.5. Col Plasmids

6.5. Plasmid DNA Manufacturing

6.5.1. Steps Involved in Plasmid DNA Manufacturing

6.6. Applications of Plasmid DNA in Pharmaceutical Industry

6.6.1. Cell and Gene Therapy Manufacturing

6.6.2. Viral Vector Manufacturing

6.6.3. Vaccine Development

6.6.4. Other Research Applications

6.7. Challenges Associated with Plasmid DNA Manufacturing

6.8. Need for Outsourcing Plasmid DNA Manufacturing

6.9. Future Perspectives

+ 7. PLASMID DNA MANUFACTURING: MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Plasmid DNA Service Providers: Overall Market Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters

7.2.4. Analysis by Type of Company

7.2.5. Analysis by Type of Venture

7.2.6. Analysis by Type of Service Offered

7.2.7. Analysis by Location of Manufacturing Facility

7.2.8. Analysis by Grade of Plasmid DNA

7.2.9. Analysis by Scale of Operation

7.2.10. Analysis by Application Area

7.2.11. Analysis by Portfolio / Offerings

+ 8. COMPANY COMPETITVENESS ANALYSIS: PLASMID DNA MANUFACTURING

8.1. Chapter Overview

8.2. Assumptions and Key Parameters

8.3. Methodology

8.4. Overview of Peer Groups

8.4.1. Peer Group I: Plasmid DNA Manufacturing Service Providers in North America

8.4.2. Peer Group II: Plasmid DNA Manufacturing Service Providers in Europe

8.4.3. Peer Group III: Plasmid DNA Manufacturing Service Providers in Asia-Pacific

8.5. Company Competitiveness Analysis

8.5.1. Plasmid DNA Manufacturing Service Providers based in North America

8.5.2. Peer Group II: Plasmid DNA Manufacturing Service Providers based in Europe

8.5.3. Peer Group III: Plasmid DNA Manufacturing Service Providers based in Asia-Pacific

+ 9. COMPANY PROFILES

9.1. Chapter Overview

9.2. Prominent Players

9.2.1. AGC Biologics

9.2.1.1. Company Overview

9.2.1.2. Service Portfolio

9.2.2. Aldevron (acquired by Danaher)

9.2.2.1. Company Overview

9.2.2.2. Service Portfolio

9.2.3. Catalent Pharma Solutions

(acquired by Novo Nordisk)

9.2.3.1. Company Overview

9.2.3.2. Service Portfolio

9.2.4. Charles River Laboratories

9.2.4.1. Company Overview

9.2.4.2. Service Portfolio

9.2.5. GenScript ProBio (a subsidiary of GenScript)

9.2.5.1. Company Overview

9.2.5.2. Service Portfolio

9.2.6. PackGene Biotech

9.2.6.1. Company Overview

9.2.6.2. Service Portfolio

9.2.7. VectorBuilder

9.2.7.1. Company Overview

9.2.7.2. Service Portfolio

9.2.8. VGXI

9.2.8.1. Company Overview

9.2.8.2. Service Portfolio

9.2.9. WuXi ATU (a subsidiary of WuXi AppTec)

9.2.9.1. Company Overview

9.2.9.2. Service Portfolio

9.2.10. Sartorius

9.2.10.1. Company Overview

9.2.10.2. Service Portfolio

9.3. Other Key Players

9.3.1. 53Biologics

9.3.1.1. Company Overview

9.3.1.2. Service Portfolio

9.3.2. ANEMOCYTE

9.3.2.1. Company Overview

9.3.2.2. Service Portfolio

9.3.3. Aurigene Pharmaceutical

Services

9.3.3.1. Company Overview

9.3.3.2. Service Portfolio

9.3.4. BioCina

9.3.4.1. Company Overview

9.3.4.2. Service Portfolio

9.3.5. 3PBiovian

9.3.5.1. Company Overview

9.3.5.2. Service Portfolio

9.3.6. Boehringer Ingelheim BioXcellence

9.3.6.1. Company Overview

9.3.6.2. Service Portfolio

9.3.7. Cytovance Biologics

9.3.7.1. Company Overview

9.3.7.2. Service Portfolio

9.3.8. Esco Aster (a subsidiary of

Esco Lifesciences)

9.3.8.1. Company Overview

9.3.8.2. Service Portfolio

9.3.9. Eurogentec (a subsidiary of Kaneka)

9.3.9.1. Company Overview

9.3.9.2. Service Portfolio

9.3.10. Forge Biologics

9.3.10.1. Company Overview

9.3.10.2. Service Portfolio

9.3.11. Hanmi Bio Plant (a Subsidiary of Hanmi Pharm)

9.3.11.1. Company Overview

9.3.11.2. Service Portfolio

9.3.12. NorthX Biologics

9.3.12.1. Company Overview

9.3.12.2. Service Portfolio

9.3.13. Patheon pharma services (acquired by Thermo Fisher Scientific)

9.3.13.1. Company Overview

9.3.13.2. Service Portfolio

9.3.14. Richter-Helm BioLogics

9.3.14.1. Company Overview

9.3.14.2. Service Portfolio

9.3.15. Southern RNA

9.3.15.1. Company Overview

9.3.15.2. Service Portfolio

+ 10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. Plasmid DNA Manufacturing Service Providers: Partnerships and Collaborations

10.3.1. Cumulative Year-wise Trend of Partnerships

10.3.2. Analysis by Type of Partnership

10.3.3. Analysis by Year and Type of Partnership

10.3.4. Analysis by Type of Partner

10.3.5. Analysis by Grade of Plasmid DNA

10.3.6. Analysis by Scale of Operation

10.3.7. Most Active Players: Analysis by Number of Partnerships

10.3.8. Analysis by Geography

10.3.8.1. Local and International Agreements

10.3.8.2. Intercontinental and Intracontinental Agreements

+ 11. ACQUISITIONS

11.1. Chapter Overview

11.2. Acquisitions Models and Key Value Drivers

11.3. Plasmid DNA Manufacturing Service Providers: Acquisitions

11.3.1. Analysis by Cumulative Year-wise Trend

11.3.2. Analysis by Type of Acquisition

11.3.3. Analysis by Year and Type of Acquisition

11.3.4. Analysis by Type of Company

11.3.5. Analysis by Business Globalization

11.3.6. Analysis by Portfolio / Expansion

11.3.7. Analysis By Type of Acquisition By Company Size of Acquirer Company

11.3.8. Analysis of Amount by Year and Type of Acquisitions

11.3.9. Most Active Players: Analysis by Number of Acquisitions

11.3.10. Most Active Players: Analysis by Number of Acquisitions

11.3.10.1. Local and International Agreements

11.3.10.2. Intercontinental and Intracontinental Agreements

+ 12. CAPACITY ANALYSIS

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Plasmid DNA Manufacturing: Global Installed Capacity

12.3.1. Analysis by Company Size

12.3.2. Analysis by Grade of Plasmid DNA

12.3.3. Analysis by Scale of Operation

12.3.4. Analysis by Location of Manufacturing Facility

12.3.4.1. Analysis of Plasmid DNA Manufacturing Capacity in North America

12.3.4.2. Analysis of Plasmid DNA Manufacturing Capacity in Europe

12.3.4.3. Analysis of Plasmid DNA Manufacturing Capacity in Asia-Pacific and Rest of the World

12.4. Concluding Remarks

+ 13. DEMAND ANALYSIS

13.1. Chapter Overview

13.2. Key Assumptions and Methodology

13.3. Global Demand for Plasmid DNA

13.3.1. Analysis by Scale of Operation

13.3.1.1. Commercial Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.1.2. Clinical Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.2. Analysis by Application Area

13.3.2.1. Overall Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.2.2. Overall Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.2.3. Overall Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.2.4. Overall Plasmid DNA Demand for DNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.2.5. Overall Plasmid DNA Demand for mRNA Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3. Analysis by Geography

13.3.3.1. Overall Demand for Plasmid DNA in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3.2. Overall Demand for Plasmid DNA in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3.3. Overall Demand for Plasmid DNA in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3.4. Overall Demand for Plasmid DNA in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3.5. Overall Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

13.3.3.6. Overall Demand for Plasmid DNA in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

+ 14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

14.1. Chapter Overview

14.2. Market Drivers

14.3. Market Restraints

14.4. Market Opportunities

14.5. Market Challenges

14.6. Conclusion

+ 15. GLOBAL PLASMID DNA MANUFACTURING MARKET

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Global Plasmid DNA Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

15.3.1. Scenario Analysis

15.3.1.1. Conservative Scenario

15.3.1.2. Optimistic Scenario

15.4. Key Market Segmentation

+ 16. PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION

16.1. Chapter Overview

16.2. Key Assumptions and Methodology

16.3. Plasmid DNA Manufacturing Market: Distribution by Scale of Operation

16.3.1. Plasmid DNA Manufacturing Market for Commercial Scale of Operation: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.3.2. Plasmid DNA Manufacturing Market for Clinical Scale of Operation: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.3.3. Plasmid DNA Manufacturing Market for Preclinical Scale of Operation: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.4. Data Triangulation and Validation

+ 17. PLASMID DNA MANUFACTURING MARKET, BY GRADE OF PLASMID DNA

17.1. Chapter Overview

17.2. Key Assumptions and Methodology

17.3. Plasmid DNA Manufacturing Market: Distribution by Grade of Plasmid DNA

17.3.1. Plasmid DNA Manufacturing Market for GMP Grade Plasmid DNA: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.3.2. Plasmid DNA Manufacturing Market for High-Quality Plasmid DNA: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.3.3. Plasmid DNA Manufacturing Market for Research Grade Plasmid DNA: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.4. Data Triangulation and Validation

+ 18. PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA

18.1. Chapter Overview

18.2. Key Assumptions and Methodology

18.3. Plasmid DNA Manufacturing Market: Distribution by Application Area

18.3.1. Plasmid DNA Manufacturing Market for Viral Vector Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.2. Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.3. Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.4. Plasmid DNA Manufacturing Market for DNA Vaccine Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.5. Plasmid DNA Manufacturing Market for mRNA Vaccine Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.4. Data Triangulation and Validation

+ 19. PLASMID DNA MANUFACTURING MARKET, BY THERAAPEUTIC AREA

19.1. Chapter Overview

19.2. Key Assumptions and Methodology

19.3. Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area

19.3.1. Plasmid DNA Manufacturing Market for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.2. Plasmid DNA Manufacturing Market for Genetic Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.3. Plasmid DNA Manufacturing Market for Infectious Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.4. Plasmid DNA Manufacturing Market for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.4. Data Triangulation and Validation

+ 20. PLASMID DNA MANUFACTURING MARKET, BY END USER

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Plasmid DNA Manufacturing Market: Distribution by End User

20.3.1. Plasmid DNA Manufacturing Market for Pharma / Biotech Companies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20.3.2. Plasmid DNA Manufacturing Market for Academic and Research Institutes: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20.3.3. Plasmid DNA Manufacturing Market for Other End-Users: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20.4. Data Triangulation and Validation

+ 21. PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. Plasmid DNA Manufacturing Market: Distribution by Geographical Regions

21.3.1. Plasmid DNA Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.2. Plasmid DNA Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.3. Plasmid DNA Manufacturing Market in Asia-Pacific: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.4. Plasmid DNA Manufacturing Market in Latin America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.5. Plasmid DNA Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.6. Plasmid DNA Manufacturing Market in Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.4. Data Triangulation and Validation

+ 22. CONCLUSION

22.1. Chapter Overview

+ 23. EXECUTIVE INSIGHTS

23.1. Chapter Overview

23.2. Company A

23.2.1. Company Snapshot

23.2.2. Interview Transcript: Chief Executive Officer and Co-Founder

23.3. Company B

23.3.1. Company Snapshot

23.3.2. Interview Transcript: Senior Director

23.4. Company C

23.4.1. Company Snapshot

23.4.2. Interview Transcript: Senior Director Commercial

23.5. Company D

23.5.1. Company Snapshot

23.5.2. Interview Transcript: Business Development Manager

23.6. Company E

23.6.1. Company Snapshot

23.6.2. Interview Transcript: Client Engagement Manager

23.7. Company F

23.7.1. Company Snapshot

23.7.2. Interview Transcript: Founder

23.8. Company G

23.8.1. Company Snapshot

23.8.2. Interview Transcript: Chief Scientific Officer

23.9. Company H

23.9.1. Company Snapshot

23.9.2. Interview Transcript: Associate Director

23.10. Company I

23.10.1. Company Snapshot

23.10.2. Interview Transcript: Senior Vice President & General Manager

23.11. Company J

23.11.1. Company Snapshot

23.11.2. Interview Transcript: Vice President, Corporate Development

23.12. Company K

23.12.1. Company Snapshot

23.12.2. Interview Transcript: Senior Scientist

23.13. Company L

23.13.1. Company Snapshot

23.13.2. Interview Transcript: Process Development Scientist

23.14. Company M

23.14.1. Company Snapshot

23.14.2. Interview Transcript: Head of Manufacturing GMP Grade

23.15. Company N

23.15.1. Company Snapshot

23.15.2. Interview Transcript: Chief Technical Officer; Founder; Senior Consultant and Chief Technical Operations Officer

23.16. Company O

23.16.1. Company Snapshot

23.16.2. Interview Transcript: Technical Support for Plasmid DNA Platform

23.17. Company P

23.17.1. Company Snapshot

23.17.2. Interview Transcript: Global CMC Manager

+ 24. APPENDIX I: TABULATED DATA
+ 25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends (I/II)

Figure 5.3 Executive Summary: Market Trends (II/II)

Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Structure of a Plasmid DNA

Figure 6.2 Steps Involved in Plasmid DNA Manufacturing

Figure 6.3 Challenges Associated with Plasmid DNA Manufacturing

Figure 7.1 Plasmid DNA Service Providers: Distribution by Year of Establishment

Figure 7.2 Plasmid DNA Service Providers: Distribution by Company Size

Figure 7.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters (Region)

Figure 7.4 Plasmid DNA Service Providers: Distribution by Location of Headquarters (Country)

Figure 7.5 Plasmid DNA Service Providers: Distribution by Type of Company

Figure 7.6 Plasmid DNA Service Providers: Distribution by Type of Venture

Figure 7.7 Plasmid DNA Service Providers: Distribution by Type of Service Offered

Figure 7.8 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility

Figure 7.9 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA

Figure 7.10 Plasmid DNA Service Providers: Distribution by Scale of Operation

Figure 7.11 Plasmid DNA Service Providers: Distribution by Application Area

Figure 7.12 Plasmid DNA Service Providers: Distribution by Portfolio / Offerings

Figure 8.1 Company Competitiveness Analysis: Overview of Plasmid DNA Manufacturing Service Providers in North America (Peer Group I)

Figure 8.2 Company Competitiveness Analysis: Overview of Plasmid DNA Manufacturing Service Providers in Europe (Peer Group II)

Figure 8.3 Company Competitiveness Analysis: Overview of Plasmid DNA Manufacturing Service Providers in Asia-Pacific (Peer Group III)

Figure 8.4 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers based in North America (Peer Group I)

Figure 8.5 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers based in Europe (Peer Group II)

Figure 8.6 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers based in Asia-Pacific (Peer Group III)

Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Since Pre-2021

Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner

Figure 10.5 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA

Figure 10.6 Partnerships and Collaborations: Distribution by Scale of Operation

Figure 10.7 Most Active Players: Distribution by Number of Partnerships

Figure 10.8 Partnerships and Collaborations: Local and International Agreements

Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Figure 11.1 Acquisitions: Cumulative Year-Wise Trend, Since Pre-2021

Figure 11.2 Acquisitions: Distribution by Type of Acquisition

Figure 11.3 Acquisitions: Distribution by Year and Type of Acquisition

Figure 11.4 Acquisitions: Distribution by Type of Company

Figure 11.5 Acquisitions: Distribution by Business Globalization

Figure 11.6 Acquisitions: Distribution by Portfolio Addition / Expansion

Figure 11.7 Acquisitions: Distribution of Type of Acquisition by Company Size of Acquirer Company

Figure 11.8 Acquisitions: Distribution of Amount by Year and Type of Acquisitions

Figure 11.9 Most Active Players: Distribution by Number of Acquisitions

Figure 11.10 Acquisitions: Local and International

Figure 11.11 Acquisitions: Intercontinental and Intracontinental

Figure 12.1 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size

Figure 12.2 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Grade of Plasmid DNA

Figure 12.3 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation

Figure 12.4 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility

Figure 12.5 Installed Plasmid DNA Manufacturing Capacity in North America (in Liters)

Figure 12.6 Installed Plasmid DNA Manufacturing Capacity in Europe (in Liters)

Figure 12.7 Installed Plasmid DNA Manufacturing Capacity in Asia-Pacific (in Liters)

Figure 13.1 Global Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.2 Commercial Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.3 Clinical Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.4 Overall Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.5 Overall Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.6 Overall Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.7 Plasmid DNA Demand for DNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.8 Overall Plasmid DNA Demand for mRNA Therapy Manufacturing, Historical Trends (2020-2025) And Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.9 Overall Demand for Plasmid DNA in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.10 Overall Demand for Plasmid DNA in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.11 Overall Demand for Plasmid DNA in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.12 Overall Demand for Plasmid DNA in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 13.13 Overall Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates Till 2035) (In Kgs)

Figure 13.14 Overall Demand for Plasmid DNA in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Figure 14.1 Market Drivers

Figure 14.2 Market Restraints

Figure 14.3 Market Opportunities

Figure 14.4 Market Challenges

Figure 15.1 Global Plasmid DNA Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 15.2 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (Till 2035), Conservative Scenario (USD Million)

Figure 15.3 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (Till 2035), Optimistic Scenario (USD Million)

Figure 16.1 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation

Figure 16.2 Plasmid DNA Manufacturing Market for Commercial Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 16.3 Plasmid DNA Manufacturing Market for Clinical Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 16.4 Plasmid DNA Manufacturing Market for Preclinical Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 17.1 Plasmid DNA Manufacturing Market: Distribution by Grade of Plasmid DNA

Figure 17.2 Plasmid DNA Manufacturing Market for GMP Grade Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 17.3 Plasmid DNA Manufacturing Market for High Quality Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 17.4 Plasmid DNA Manufacturing Market for Research Grade Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.1 Plasmid DNA Manufacturing Market: Distribution by Application Area

Figure 18.2 Plasmid DNA Manufacturing Market for Viral Vector Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.3 Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.4 Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.5 Plasmid DNA Manufacturing Market for DNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 18.6 Plasmid DNA Manufacturing Market for mRNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.1 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area

Figure 19.2 Plasmid DNA Manufacturing Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.3 Plasmid DNA Manufacturing Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.4 Plasmid DNA Manufacturing Market for Infectious Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.5 Plasmid DNA Manufacturing Market for Other Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 20.1 Plasmid DNA Manufacturing Market: Distribution by End-Users

Figure 20.2 Plasmid DNA Manufacturing Market for Pharma / Biotech Companies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million

Figure 20.3 Plasmid DNA Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 20.4 Plasmid DNA Manufacturing Market for Other End-Users, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.1 Plasmid DNA Manufacturing Market: Distribution by Geographical Regions

Figure 21.2 Plasmid DNA Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.3 Plasmid DNA Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.4 Plasmid DNA Manufacturing Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.5 Plasmid DNA Manufacturing Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.6 Plasmid DNA Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 21.7 Plasmid DNA Manufacturing Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Figure 22.1 Concluding Remarks: Plasmid DNA Manufacturing Market Landscape

Figure 22.2 Concluding Remarks: Plasmid DNA Manufacturing Partnerships and Collaborations

Figure 22.3 Concluding Remarks: Plasmid DNA Manufacturing Acquisitions

Figure 22.4 Concluding Remarks: Plasmid DNA Manufacturing Capacity Analysis Manufacturing Demand Analysis

Figure 22.5 Concluding Remarks: Plasmid DNA Manufacturing Market

+ List of Tables

Table 7.1 List of Plasmid DNA Service Providers

Table 7.2 Plasmid DNA Service Providers: Information on Type of Service Offered

Table 7.3 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility

Table 7.4 Plasmid DNA Service Providers: Information on Grade of Plasmid DNA

Table 7.5 Plasmid DNA Service Providers: Information on Scale of Operation

Table 7.6 Plasmid DNA Service Providers: Information on Application Area

Table 7.7 Plasmid DNA Service Providers: Portfolio / Offerings

Table 8.1 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers Based in North America (Peer Group I)

Table 8.2 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers Based in Europe (Peer Group II)

Table 8.3 Company Competitiveness Analysis: Plasmid DNA Manufacturing Service Providers Based in Asia-Pacific (Peer Group III)

Table 9.1 List of Companies Profiled

Table 9.2 AGC Biologics: Company Overview

Table 9.3 AGC Biologics: Service Portfolio

Table 9.4 Aldevron (acquired by Danaher): Company Overview

Table 9.5 Aldevron (acquired by Danaher): Service Portfolio

Table 9.6 Catalent Pharma Solutions (acquired by Novo Nordisk): Company Overview

Table 9.7 Catalent Pharma Solutions: Service Portfolio

Table 9.8 Charles River Laboratories: Company Overview

Table 9.9 Charles River Laboratories: Service Portfolio

Table 9.10 GenScript ProBio (a subsidiary of GenScript): Company Overview

Table 9.11 GenScript ProBio (a subsidiary of GenScript): Service Portfolio

Table 9.12 PackGene Biotech: Company Overview

Table 9.13 PackGene Biotech: Service Portfolio

Table 9.14 VectorBuilder: Company Overview

Table 9.15 VectorBuilder: Service Portfolio

Table 9.16 VGXI: Company Overview

Table 9.17 VGXI: Service Portfolio

Table 9.18 WuXi ATU (a subsidiary of WuXi AppTec): Company Overview

Table 9.19 WuXi ATU (a subsidiary of WuXi AppTec): Service Portfolio

Table 9.20 Sartorius: Company Overview

Table 9.21 Sartorius: Service Portfolio

Table 9.22 53Biologics: Company Overview

Table 9.23 53Biologics: Service Portfolio

Table 9.24 ANEMOCYTE: Company Overview

Table 9.25 ANEMOCYTE: Service Portfolio

Table 9.26 Sartorius: Company Overview

Table 9.27 Sartorius: Service Portfolio

Table 9.28 Aurigene Pharmaceutical Services: Company Overview

Table 9.29 Aurigene Pharmaceutical Services: Service Portfolio

Table 9.30 BioCina: Company Overview

Table 9.31 BioCina: Service Portfolio

Table 9.32 3PBiovian: Company Overview

Table 9.33 3PBiovian: Service Portfolio

Table 9.34 Boehringer Ingelheim BioXcellence: Company Overview

Table 9.35 Boehringer Ingelheim BioXcellence: Service Portfolio

Table 9.36 Cytovance Biologics: Company Overview

Table 9.37 Cytovance Biologics: Service Portfolio

Table 9.38 Esco Aster (a subsidiary of Esco Lifesciences): Company Overview

Table 9.39 Esco Aster (a Subsidiary of Esco Lifesciences): Service Portfolio

Table 9.40 Eurogentec (a subsidiary of Kaneka): Company Overview

Table 9.41 Eurogentec (a subsidiary of Kaneka): Service Portfolio

Table 9.42 Forge Biologics: Company Overview

Table 9.43 Forge Biologics: Service Portfolio

Table 9.44 Hanmi Bio Plant (a Subsidiary of Hanmi Pharm): Company Overview

Table 9.45 Hanmi Bio Plant (a Subsidiary of Hanmi Pharm): Service Portfolio

Table 9.46 NorthX Biologics: Company Overview

Table 9.47 NorthX Biologics: Service Portfolio

Table 9.48 Patheon pharma services (acquired by Thermo Fisher Scientific): Company Overview

Table 9.49 Patheon pharma services (acquired by Thermo Fisher Scientific): Service Portfolio

Table 9.50 Richter-Helm BioLogics: Company Overview

Table 9.51 Richter-Helm BioLogics: Service Portfolio

Table 9.52 Southern RNA: Company Overview

Table 9.53 Southern RNA: Service Portfolio

Table 10.1 Plasmid DNA Service Providers: List of Partnerships and Collaborations

Table 11.1 Plasmid DNA Manufacturing Service Providers: List of Acquisitions, Since Pre-2021

Table 12.1 Plasmid DNA Manufacturers: Information on Production Capacity (Sample Dataset)

Table 12.2 Installed Plasmid DNA Manufacturing Capacity: Average Capacity Per Facility based on Company Size (Sample Dataset)

Table 12.3 Plasmid DNA Manufacturers: Global Plasmid DNA Production Capacity

Table 24.1 Plasmid DNA Service Providers: Distribution by Year of Establishment

Table 24.2 Plasmid DNA Service Providers: Distribution by Company Size

Table 24.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters

Table 24.4 Plasmid DNA Service Providers: Distribution by Type of Company

Table 24.5 Plasmid DNA Service Providers: Distribution by Type of Venture

Table 24.6 Plasmid DNA Service Providers: Distribution by Type of Service Offered

Table 24.7 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility

Table 24.8 Plasmid DNA Service Providers: Distribution by Key Offerings

Table 24.9 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA

Table 24.10 Plasmid DNA Service Providers: Distribution by Scale of Operation

Table 24.11 Plasmid DNA Service Providers: Distribution by Application Area

Table 24.12 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2021-2026

Table 24.13 Partnerships and Collaborations: Distribution by Type of Partnership

Table 24.14 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 24.15 Partnerships and Collaborations: Distribution by Type of Partner

Table 24.16 Partnerships and Collaborations: Distribution by Type of Partner (Specific)

Table 24.17 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA

Table 24.18 Partnerships and Collaborations: Distribution by Scale of Operation

Table 24.19 Most Active Players: Distribution by Number of Partnerships

Table 24.20 Partnerships and Collaborations: Local and International Agreements

Table 24.21 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Table 24.22 Acquisitions: Cumulative Year-Wise Trend, Pre-2021-2026

Table 24.23 Acquisitions: Distribution by Type of Acquisition

Table 24.24 Acquisitions: Distribution by Type of Company

Table 24.25 Acquisitions: Distribution by Business Globalization

Table 24.26 Acquisitions: Distribution by Portfolio Addition / Expansion

Table 24.27 Acquisitions: Distribution by Type of Acquisition by Company Size

Table 24.28 Most Active Players: Distribution by Number of Acquisitions

Table 24.29 Acquisitions: Local and International Deals

Table 24.30 Acquisitions: Intercontinental and Intracontinental Deals

Table 24.31 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size

Table 24.32 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Grade of Plasmid DNA

Table 24.33 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation

Table 24.34 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility

Table 24.35 Global Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.36 Commercial Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.37 Clinical Demand for Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.38 Overall Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.39 Overall Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.40 Overall Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.41 Overall Plasmid DNA Demand for DNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.42 Overall Plasmid DNA Demand for mRNA Therapy Manufacturing, Historical Trends (Since 2023) And Forecasted Estimates (Till 2035) (In Kgs)

Table 24.43 Overall Plasmid DNA Demand in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.44 Overall Plasmid DNA Demand in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.45 Overall Plasmid DNA Demand in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.46 Overall Plasmid DNA Demand in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.47 Overall Plasmid DNA Demand in Middle East and North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.48 Overall Plasmid DNA Demand in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (In Kgs)

Table 24.49 Global Plasmid DNA Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.50 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)

Table 24.51 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)

Table 24.52 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation (USD Million)

Table 24.53 Plasmid DNA Manufacturing Market for Commercial Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.54 Plasmid DNA Manufacturing Market for Clinical Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.55 Plasmid DNA Manufacturing Market for Preclinical Scale of Operation, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.56 Plasmid DNA Manufacturing Market: Distribution by Grade of Plasmid DNA (USD Million)

Table 24.57 Plasmid DNA Manufacturing Market for GMP Grade Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.58 Plasmid DNA Manufacturing Market for High Quality Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.59 Plasmid DNA Manufacturing Market for Research Grade Plasmid DNA, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.60 Plasmid DNA Manufacturing Market: Distribution by Application Area (USD Million)

Table 24.61 Plasmid DNA Manufacturing Market for Viral Vector Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.62 Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.63 Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.64 Plasmid DNA Manufacturing Market for DNA Vaccines Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.65 Plasmid DNA Manufacturing Market for mRNA Vaccine Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.66 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area (USD Million)

Table 24.67 Plasmid DNA Manufacturing Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.68 Plasmid DNA Manufacturing Market for Genetic Diseases, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.69 Plasmid DNA Manufacturing Market for Infectious Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.70 Plasmid DNA Manufacturing Market for Other Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.71 Plasmid DNA Manufacturing Market: Distribution by End-User (USD Million)

Table 24.72 Plasmid DNA Manufacturing Market for Pharma / Biotech Companies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.73 Plasmid DNA Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.74 Plasmid DNA Manufacturing Market for Other End-Users, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.75 Plasmid DNA Manufacturing Market: Distribution by Geographical Regions (USD Million)

Table 24.76 Plasmid DNA Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.77 Plasmid DNA Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.78 Plasmid DNA Manufacturing Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.79 Plasmid DNA Manufacturing Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.80 Plasmid DNA Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)

Table 24.81 Plasmid DNA Manufacturing Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)